About us
———
Wuhan Hongren Biopharmaceuticals Inc., founded in 2011, is a CRO of drug research and development technology services for clinical bioanalysis and non-clinical pharmacokinetic research. It is at the forefront of the industry in many subdivided service fields. The lab space in Wuhan, Shanghai and Guangzhou exceeds 18,000 m2, with a bioanalysis platform conforming to the GLP. Hongren Biopharma is committed to providing drug R&D services for Pharma & biotech, clinical research center and drug R&D institution and other partners, to help accelerate the process of drug commercialization.
Rich in experience
Reliable quality
1800+

Innovative drugs/generic drugs Clinical PK+BE+ADA+PD projectss

500+

non-clinical pharmacokinetic projects experience

130+

On-site inspection organized by CFDI NMPA

500+

Approvals of new drug certificate or drug manufacturing

certificate by NMPA

Main Services
—————
Clinical Bioanalysis
Data management and statistics
Pre-clinical studies
CMC
News

Research on Novel Delivery System drug DMPK in New Drug Research and development and its cases Share | Hongren Report of the 14th Academic Conference on Drug and Chemical Foreign Body Metabolism of Chinese Pharmacological Society

Non-clinical and clinical DMPK studies of the new delivery system provide data support for elaborating the characteristics of ADME in vivo. Robust bioanalytical methods are critical. New delivery syst

The application of chemical derivatization technology in biological analysis |

In general, compounds suitable for LC-MS analysis need to have the following characteristics: good chemical stability, easy ionization (ESI, APCI), high abundance, good selectivity of product ions,...

[Big coffee gathers in Wuhan East Lake, bright spots] 132+615 pharmaceutical colleagues talk about the frontier of medicine and seek the future of the industry!

The First Wuhan East Lake Biomedical Innovation and Development Forum, co-sponsored by Hongren Pharmaceutical and Tongji Medical College of Huazhong University of Science and Technology, was successfu

【 Macropharma 】 Structural characterization of ADC drugs and case sharing

Antibody-drug conjugates (ADCs) consist of three main components: Antibodies that selectively recognize antigens on the surface of cancer cells, drug payloads that kill cancer cells, and linkers th...

Common problems and solutions for bioanalysis of polypeptide drugs based on LC-MS detection platform

The biological analysis of polypeptide mainly includes PK pharmacokinetic test, TK pharmacokinetic test and ADA test. The methods used in the analysis mainly include LC-MS/MS and LBA ligand receptor

Key considerations and cases of mesenchymal stem Cell bioanalysis Share | Hongren Pharma Report of the 2nd Greater Bay Area Cell Gene Therapy Development Forum

Biological analysis of stem cells mainly includes: 1, PK and distribution. Among them, clinical distribution detection is difficult due to the limitation of sample sampling. 2. Immunogenicity assessme
—— Contact us ——
【 Contact information 】
Add: Building C1/B4/B6, Optical Valley Biological City, No. 666, Gaoxin Avenue, East East East Lake High-tech Zone, Wuhan
Laboratory Building 2, Zone F, Guoying Industrial Park, No. 666, Shendun Fourth Road, East Lake High-tech Zone, Wuhan
Building 1, Hengyue International Building, Lane 1238, Zhangjiang Road, Pudong, Shanghai
Building C5, Technology Enterprise Accelerator, No.11, Kaiyuan Avenue, Huangpu District, Guangzhou
Postal Code: 430075
【 Service consulting 】
Tel: +86 15997130414 (Ms. Qian) QQ ：2824415271
Mailbox：hongren@hrbiopharm.com
hr-service@hrbiopharm.com